DRUG · GROUP
KEY RECEPTORS
DISTINCT USE
SIGNATURE ADVERSE
Haloperidol · fluphenazine
Strong D2 block (high potency)
Acute agitation, delirium, Tourette; depot injection
EPS, NMS, hyperprolactinemia, QT (IV haloperidol)
Chlorpromazine · thioridazine
Weak D2; strong M, α1, H1
Psychosis (rare now), intractable hiccups
Sedation, orthostasis, anticholinergic; thioridazine retinitis pigmentosa, QT
Risperidone · paliperidone
D2 + 5-HT2A
Schizophrenia, bipolar mania, autism irritability
Hyperprolactinemia (galactorrhea, amenorrhea, gynecomastia), EPS at high dose
D2 + 5-HT2A + H1, M
Schizophrenia, bipolar, agitation
Marked weight gain, diabetes, dyslipidemia
Weak D2, strong H1
Bipolar depression, PD psychosis, adjunct MDD
Sedation, orthostasis, metabolic effects, cataracts (animal)
D2 + 5-HT2A
Schizophrenia, bipolar depression (lurasidone)
QT (ziprasidone); take with food; low metabolic risk
Aripiprazole · brexpiprazole · cariprazine
D2 partial agonists
Schizophrenia, bipolar, adjunct MDD, Tourette
Akathisia; low prolactin and metabolic effects
Weak D2, D4, 5-HT2A, many others
Treatment-resistant schizophrenia, suicidal patients, PD psychosis
Agranulocytosis (ANC monitoring), seizures, myocarditis, sialorrhea, ileus, weight gain
Sudden D2 block in nigrostriatal pathway
Hours–days: torticollis, oculogyric crisis
Benztropine or diphenhydramine
Inner restlessness
Days–weeks
Propranolol, benzodiazepine, lower dose
Drug-induced parkinsonism
Nigrostriatal D2 block
Weeks: bradykinesia, rigidity, tremor
Benztropine, amantadine
D2 receptor upregulation after chronic block
Months–years: orofacial chewing, lip smacking
Valbenazine/deutetrabenazine; switch to clozapine; often irreversible
Neuroleptic malignant syndrome
Sudden profound D2 block
Fever, lead-pipe rigidity, delirium, labile BP, ↑ CK, myoglobinuria
Stop drug, cool, dantrolene, bromocriptine